Company profile for Actimed Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are focused on bringing innovation to the treatment of cachexia with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives, restore their dignity and ease the burden for the patient, carer and provider. Cachexia is a wasting disease that accompanies cancer and other serious chronic illnesses and is associated with significant morbidity and mortality...
We are focused on bringing innovation to the treatment of cachexia with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives, restore their dignity and ease the burden for the patient, carer and provider. Cachexia is a wasting disease that accompanies cancer and other serious chronic illnesses and is associated with significant morbidity and mortality. Despite its prevalence and devastating clinical effects, there is no approved drug for the treatment or prevention of cancer-related cachexia.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
The Old Bakehouse, Course Road, Ascot, Berkshire, SL5 7HL.
Telephone
Telephone
10519588
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://actimedtherapeutics.com/news/40/54/Actimed-Therapeutics-Announces-Strategic-Licensing-Agreement-with-Mankind-Pharma.html

PRESS RELEASE
22 Nov 2025

https://www.globenewswire.com/news-release/2025/06/25/3104816/0/en/Actimed-Therapeutics-Enrolls-First-Patients-in-Phase-2a-PROACT-Study-Programme-to-Assess-S-pindolol-benzoate-in-Obese-Patients-During-and-Post-GLP-1-Agonist-Therapy.html

GLOBENEWSWIRE
25 Jun 2025

https://www.globenewswire.com/news-release/2025/05/20/3084550/0/en/Actimed-Therapeutics-Announces-New-Programme-to-Investigate-Potential-Muscle-Preservation-Effects-of-S-pindolol-Benzoate-in-Obese-Patients-Treated-with-GLP-1-Agonists.html

GLOBENEWSWIRE
20 May 2025

https://www.globenewswire.com/news-release/2025/04/24/3067112/0/en/Actimed-Therapeutics-Appoints-Shaun-Claydon-as-Chief-Financial-Officer.html

GLOBENEWSWIRE
24 Apr 2025

https://www.globenewswire.com/news-release/2025/02/06/3021736/0/en/Actimed-Therapeutics-Expands-Intellectual-Property-Portfolio.html

GLOBENEWSWIRE
06 Feb 2025

https://www.globenewswire.com/news-release/2025/01/16/3010552/0/en/Actimed-Therapeutics-appoints-Dr-Fabio-Dorigotti-as-Chief-Medical-Officer-to-drive-further-pipeline-development-for-cancer-cachexia-and-other-muscle-wasting-disorders.html

GLOBENEWSWIRE
16 Jan 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty